Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Impact of Group Management and Transfer on Individual Sociality in Highland Cattle (Bos taurus).

Sosa SO, Pelé M, Debergue É, Kuntz C, Keller B, Robic F, Siegwalt-Baudin F, Richer C, Ramos A, Sueur C.

Front Vet Sci. 2019 Jun 12;6:183. doi: 10.3389/fvets.2019.00183. eCollection 2019.

2.

Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation.

Da Costa EM, Armaos G, McInnes G, Beaudry A, Moquin-Beaudry G, Bertrand-Lehouillier V, Caron M, Richer C, St-Onge P, Johnson JR, Krogan N, Sai Y, Downey M, Rafei M, Boileau M, Eppert K, Flores-Díaz E, Haman A, Hoang T, Sinnett D, Beauséjour C, McGraw S, Raynal NJ.

J Exp Clin Cancer Res. 2019 Jun 13;38(1):251. doi: 10.1186/s13046-019-1242-8.

3.

miR-431-5p Knockdown Protects Against Angiotensin II-Induced Hypertension and Vascular Injury.

Huo KG, Richer C, Berillo O, Mahjoub N, Fraulob-Aquino JC, Barhoumi T, Ouerd S, Coelho SC, Sinnett D, Paradis P, Schiffrin EL.

Hypertension. 2019 May;73(5):1007-1017. doi: 10.1161/HYPERTENSIONAHA.119.12619.

PMID:
30929512
4.

Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma.

Khater F, Langlois S, Cassart P, Roy AM, Lajoie M, Healy J, Richer C, St-Onge P, Piché N, Perreault S, Cellot S, Marzouki M, Jabado N, Sinnett D.

Oncogene. 2019 Apr;38(16):2994-3002. doi: 10.1038/s41388-018-0623-3. Epub 2018 Dec 21.

5.

Very long intergenic non-coding RNA transcripts and expression profiles are associated to specific childhood acute lymphoblastic leukemia subtypes.

Caron M, St-Onge P, Drouin S, Richer C, Sontag T, Busche S, Bourque G, Pastinen T, Sinnett D.

PLoS One. 2018 Nov 15;13(11):e0207250. doi: 10.1371/journal.pone.0207250. eCollection 2018.

6.

Genome wide mapping of ETV6 binding sites in pre-B leukemic cells.

Neveu B, Caron M, Lagacé K, Richer C, Sinnett D.

Sci Rep. 2018 Oct 19;8(1):15526. doi: 10.1038/s41598-018-33947-1.

7.

Mutational dynamics of early and late relapsed childhood ALL: rapid clonal expansion and long-term dormancy.

Spinella JF, Richer C, Cassart P, Ouimet M, Healy J, Sinnett D.

Blood Adv. 2018 Feb 13;2(3):177-188. doi: 10.1182/bloodadvances.2017011510.

8.

[Is cancer incidence different between type 2 diabetes patients compared to non-diabetics in hemodialysis? A study from the REIN registry].

Le Guillou A, Pladys A, Kihal W, Siebert M, Haddj-Elmrabet A, Cernon C, Bernard A, Charasse C, Mandart L, Hamel D, Tanquerel T, Strullu B, Richer C, Siohan P, Sawadogo T, Baleynaud J, Baluta S, Bayat S, Vigneau C.

Nephrol Ther. 2018 May;14(3):142-147. doi: 10.1016/j.nephro.2017.02.018. Epub 2017 Dec 6. French.

PMID:
29223661
9.

LncRNAs downregulated in childhood acute lymphoblastic leukemia modulate apoptosis, cell migration, and DNA damage response.

Gioia R, Drouin S, Ouimet M, Caron M, St-Onge P, Richer C, Sinnett D.

Oncotarget. 2017 Sep 11;8(46):80645-80650. doi: 10.18632/oncotarget.20817. eCollection 2017 Oct 6.

10.

Specific expression of novel long non-coding RNAs in high-hyperdiploid childhood acute lymphoblastic leukemia.

Lajoie M, Drouin S, Caron M, St-Onge P, Ouimet M, Gioia R, Lafond MH, Vidal R, Richer C, Oualkacha K, Droit A, Sinnett D.

PLoS One. 2017 Mar 27;12(3):e0174124. doi: 10.1371/journal.pone.0174124. eCollection 2017.

11.

KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia.

Khater F, Lajoie M, Langlois S, Healy J, Cellot S, Richer C, Beaulieu P, St-Onge P, Saillour V, Minden M, Marzouki M, Krajinovic M, Bittencourt H, Sinnett D.

Blood. 2017 Mar 23;129(12):1729-1732. doi: 10.1182/blood-2016-10-744219. Epub 2017 Jan 9. No abstract available.

12.

A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration.

Ouimet M, Drouin S, Lajoie M, Caron M, St-Onge P, Gioia R, Richer C, Sinnett D.

Oncotarget. 2017 Jan 31;8(5):7477-7488. doi: 10.18632/oncotarget.13936.

13.

SNooPer: a machine learning-based method for somatic variant identification from low-pass next-generation sequencing.

Spinella JF, Mehanna P, Vidal R, Saillour V, Cassart P, Richer C, Ouimet M, Healy J, Sinnett D.

BMC Genomics. 2016 Nov 14;17(1):912.

14.

Kallikrein(K1)-kinin-kininase (ACE) and end-organ damage in ischemia and diabetes: therapeutic implications.

Desposito D, Waeckel L, Potier L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F.

Biol Chem. 2016 Dec 1;397(12):1217-1222. doi: 10.1515/hsz-2016-0228. Review.

PMID:
27622831
15.

Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.

Spinella JF, Cassart P, Richer C, Saillour V, Ouimet M, Langlois S, St-Onge P, Sontag T, Healy J, Minden MD, Sinnett D.

Oncotarget. 2016 Oct 4;7(40):65485-65503. doi: 10.18632/oncotarget.11796.

16.

CLIC5: a novel ETV6 target gene in childhood acute lymphoblastic leukemia.

Neveu B, Spinella JF, Richer C, Lagacé K, Cassart P, Lajoie M, Jananji S, Drouin S, Healy J, Hickson GR, Sinnett D.

Haematologica. 2016 Dec;101(12):1534-1543. Epub 2016 Aug 18.

17.

A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells.

Spinella JF, Cassart P, Garnier N, Rousseau P, Drullion C, Richer C, Ouimet M, Saillour V, Healy J, Autexier C, Sinnett D.

BMC Cancer. 2015 Sep 7;15:621. doi: 10.1186/s12885-015-1639-5.

18.

Whole-exome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals putative predisposing mutations in Fanconi anemia genes.

Spinella JF, Healy J, Saillour V, Richer C, Cassart P, Ouimet M, Sinnett D.

BMC Cancer. 2015 Jul 23;15:539. doi: 10.1186/s12885-015-1549-6.

19.

Tissue kallikrein is required for the cardioprotective effect of cyclosporin A in myocardial ischemia in the mouse.

Youcef G, Belaidi E, Waeckel L, Fazal L, Clemessy M, Vincent MP, Zadigue G, Richer C, Alhenc-Gelas F, Ovize M, Pizard A.

Biochem Pharmacol. 2015 Mar 1;94(1):22-9. doi: 10.1016/j.bcp.2015.01.007. Epub 2015 Jan 23.

PMID:
25623731
20.

The RNA-binding protein Staufen1 impairs myogenic differentiation via a c-myc-dependent mechanism.

Ravel-Chapuis A, Crawford TE, Blais-Crépeau ML, Bélanger G, Richer CT, Jasmin BJ.

Mol Biol Cell. 2014 Nov 15;25(23):3765-78. doi: 10.1091/mbc.E14-04-0895. Epub 2014 Sep 10.

21.

Cardioprotective effect of VEGF and venom VEGF-like protein in acute myocardial ischemia in mice: effect on mitochondrial function.

Messadi E, Aloui Z, Belaidi E, Vincent MP, Couture-Lepetit E, Waeckel L, Decorps J, Bouby N, Gasmi A, Karoui H, Ovize M, Alhenc-Gelas F, Richer C.

J Cardiovasc Pharmacol. 2014 Mar;63(3):274-81. doi: 10.1097/FJC.0000000000000045.

PMID:
24220315
22.

Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia.

Sanchez R, St-Cyr J, Lalonde ME, Healy J, Richer C, Gagné V, Laverdière C, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Kritikou EA, Krajinovic M, Sinnett D.

Haematologica. 2014 Feb;99(2):314-21. doi: 10.3324/haematol.2013.085340. Epub 2013 Sep 13.

23.

Integration of high-resolution methylome and transcriptome analyses to dissect epigenomic changes in childhood acute lymphoblastic leukemia.

Busche S, Ge B, Vidal R, Spinella JF, Saillour V, Richer C, Healy J, Chen SH, Droit A, Sinnett D, Pastinen T.

Cancer Res. 2013 Jul 15;73(14):4323-36. doi: 10.1158/0008-5472.CAN-12-4367. Epub 2013 May 30.

24.

Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes.

Potier L, Waeckel L, Vincent MP, Chollet C, Gobeil F Jr, Marre M, Bruneval P, Richer C, Roussel R, Alhenc-Gelas F, Bouby N.

J Pharmacol Exp Ther. 2013 Jul;346(1):23-30. doi: 10.1124/jpet.113.203927. Epub 2013 Apr 16.

PMID:
23591995
25.

Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man.

Waeckel L, Potier L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F.

Thromb Haemost. 2013 Sep;110(3):476-83. doi: 10.1160/TH12-12-0937. Epub 2013 Apr 4. Review.

PMID:
23572029
26.

Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.

Potier L, Waeckel L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F.

Biol Chem. 2013 Mar;394(3):329-33. doi: 10.1515/hsz-2012-0332. Review.

PMID:
23324381
27.

Kinins as therapeutic agents in cardiovascular and renal diseases.

Alhenc-Gelas F, Bouby N, Richer C, Potier L, Roussel R, Marre M.

Curr Pharm Des. 2011;17(25):2654-62. Review.

PMID:
21728987
28.

ALG: automated genotype calling of Luminex assays.

Bourgey M, Lariviere M, Richer C, Sinnett D.

PLoS One. 2011 May 6;6(5):e19368. doi: 10.1371/journal.pone.0019368.

29.

Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells.

Spinetti G, Fortunato O, Cordella D, Portararo P, Kränkel N, Katare R, Sala-Newby GB, Richer C, Vincent MP, Alhenc-Gelas F, Tonolo G, Cherchi S, Emanueli C, Madeddu P.

Circ Res. 2011 Feb 4;108(3):284-93. doi: 10.1161/CIRCRESAHA.110.236786. Epub 2010 Dec 16.

30.

Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia.

Messadi E, Vincent MP, Griol-Charhbili V, Mandet C, Colucci J, Krege JH, Bruneval P, Bouby N, Smithies O, Alhenc-Gelas F, Richer C.

FASEB J. 2010 Dec;24(12):4691-700. doi: 10.1096/fj.10-165902. Epub 2010 Jul 28.

31.

Detection of fetomaternal genotype associations in early-onset disorders: evaluation of different methods and their application to childhood leukemia.

Healy J, Bourgey M, Richer C, Sinnett D, Roy-Gagnon MH.

J Biomed Biotechnol. 2010;2010:369534. doi: 10.1155/2010/369534. Epub 2010 Jun 9.

32.

Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia.

Healy J, Richer C, Bourgey M, Kritikou EA, Sinnett D.

Haematologica. 2010 Sep;95(9):1608-11. doi: 10.3324/haematol.2010.022459. Epub 2010 May 11.

33.

Tissue kallikrein deficiency and renovascular hypertension in the mouse.

Griol-Charhbili V, Sabbah L, Colucci J, Vincent MP, Baudrie V, Laude D, Elghozi JL, Bruneval P, Picard N, Meneton P, Alhenc-Gelas F, Richer C.

Am J Physiol Regul Integr Comp Physiol. 2009 May;296(5):R1385-91. doi: 10.1152/ajpregu.90411.2008. Epub 2009 Feb 25.

34.

Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization.

Stone OA, Richer C, Emanueli C, van Weel V, Quax PH, Katare R, Kraenkel N, Campagnolo P, Barcelos LS, Siragusa M, Sala-Newby GB, Baldessari D, Mione M, Vincent MP, Benest AV, Al Haj Zen A, Gonzalez J, Bates DO, Alhenc-Gelas F, Madeddu P.

Arterioscler Thromb Vasc Biol. 2009 May;29(5):657-64. doi: 10.1161/ATVBAHA.108.182139. Epub 2009 Jan 22.

35.

Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney.

Pizard A, Richer C, Bouby N, Picard N, Meneton P, Azizi M, Alhenc-Gelas F.

Biol Chem. 2008 Jun;389(6):701-6. doi: 10.1515/BC.2008.081. Review.

36.

Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice.

Pons S, Griol-Charhbili V, Heymes C, Fornes P, Heudes D, Hagege A, Loyer X, Meneton P, Giudicelli JF, Samuel JL, Alhenc-Gelas F, Richer C.

Eur J Heart Fail. 2008 Apr;10(4):343-51. doi: 10.1016/j.ejheart.2008.02.002. Epub 2008 Mar 14.

37.

Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice.

Messadi-Laribi E, Griol-Charhbili V, Gaies E, Vincent MP, Heudes D, Meneton P, Alhenc-Gelas F, Richer C.

Clin Exp Pharmacol Physiol. 2008 Apr;35(4):489-93. doi: 10.1111/j.1440-1681.2008.04902.x. Review.

PMID:
18307747
38.

Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.

Messadi-Laribi E, Griol-Charhbili V, Pizard A, Vincent MP, Heudes D, Meneton P, Alhenc-Gelas F, Richer C.

J Pharmacol Exp Ther. 2007 Oct;323(1):210-6. Epub 2007 Jul 16.

PMID:
17636004
39.

Murine models of myocardial and limb ischemia: diagnostic end-points and relevance to clinical problems.

Madeddu P, Emanueli C, Spillmann F, Meloni M, Bouby N, Richer C, Alhenc-Gelas F, Van Weel V, Eefting D, Quax PH, Hu Y, Xu Q, Hemdahl AL, van Golde J, Huijberts M, de Lussanet Q, Struijker Boudier H, Couffinhal T, Duplaa C, Chimenti S, Staszewsky L, Latini R, Baumans V, Levy BI.

Vascul Pharmacol. 2006 Nov;45(5):281-301. Epub 2006 Aug 22. Review.

PMID:
17010676
40.

Plasma glutathione peroxidase activity as a potential indicator of hypoxic stress in breath-hold diving.

Rousseau AS, Richer C, Richard MJ, Favier A, Margaritis I.

Aviat Space Environ Med. 2006 May;77(5):551-5.

PMID:
16708536
41.

Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia.

Griol-Charhbili V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, Alhenc-Gelas F, Richer C.

FASEB J. 2005 Jul;19(9):1172-4. Epub 2005 Apr 28.

PMID:
15860541
42.

Mouse model of SCN5A-linked hereditary Lenègre's disease: age-related conduction slowing and myocardial fibrosis.

Royer A, van Veen TA, Le Bouter S, Marionneau C, Griol-Charhbili V, Léoni AL, Steenman M, van Rijen HV, Demolombe S, Goddard CA, Richer C, Escoubet B, Jarry-Guichard T, Colledge WH, Gros D, de Bakker JM, Grace AA, Escande D, Charpentier F.

Circulation. 2005 Apr 12;111(14):1738-46. Epub 2005 Apr 4.

PMID:
15809371
43.

Malingering on subjective complaint tasks: an exploration of the deterrent effects of warning.

Sullivan K, Richer C.

Arch Clin Neuropsychol. 2002 Oct;17(7):691-708.

44.

Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure.

Pons S, Hagège A, Fornes P, Gervais M, Giudicelli JF, Richer C.

J Cardiovasc Pharmacol. 2003 Jul;42(1):17-23.

PMID:
12827021
45.

Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice.

Gervais M, Pons S, Nicoletti A, Cosson C, Giudicelli JF, Richer C.

Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):183-9.

PMID:
12588757
46.

Survival, haemodynamics and cardiac remodelling follow up in mice after myocardial infarction.

Pons S, Fornes P, Hagege AA, Heudes D, Giudicelli JF, Richer C.

Clin Exp Pharmacol Physiol. 2003 Jan-Feb;30(1-2):25-31.

PMID:
12542449
47.
48.
49.

Coronary dilatation reserve in experimental hypertension and chronic heart failure: effects of blockade of the renin-angiotensin system.

Richer C, Domergue V, Gervais M, Fornes P, Trabold F, Giudicelli JF.

Clin Exp Pharmacol Physiol. 2001 Dec;28(12):997-1001.

PMID:
11903302
50.

Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia.

Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D.

Int J Cancer. 2002 Jan 10;97(2):230-6.

Supplemental Content

Loading ...
Support Center